Worldwide, 10 to 20 million people are infected with the hepatitis D virus (HDV). HDV infection is always associated with hepatitis B virus infection. For this most severe form of chronic viral hepatitis, there has been no satisfactory therapeutic option. In a multicenter phase II clinical trial, an international research team has now shown that the 24-week application of the compound Bulevirtide, developed by DZIF virologist Prof. Stephan Urban, significantly reduced the hepatitis D viral load in blood serum and liver. The novel entry inhibitor therefore represents a promising strategy in the treatment of chronic HDV infection.